These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 31931920)

  • 1. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
    Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
    Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
    Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
    BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
    Fleeman N; Houten R; Nevitt S; Mahon J; Beale S; Boland A; Greenhalgh J; Edwards K; Maden M; Bhattacharyya D; Chaplin M; McEntee J; Chow S; Waddell T
    Health Technol Assess; 2024 Aug; 28(49):1-190. PubMed ID: 39252678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 9. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
    Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
    Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
    Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
    Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
    Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
    Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 16. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
    Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
    Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.